Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
https://link.springer.com/content/pdf/10.1007/s00262-020-02786-3.pdf
Reference70 articles.
1. Pardoll D (2015) Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol 42:523–538
2. Derosa L et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer. Ann Oncol 29:1437–1444
3. Motzer RJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813
4. Escudier B et al (2017) CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. EurUrol. https://doi.org/10.1016/j.eururo.2017.02.010
5. Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer;Heliyon;2024-07
2. Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer;npj Breast Cancer;2024-03-26
3. Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer;2024-01-30
4. Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy;Journal of Oncology Pharmacy Practice;2023-08-10
5. Association of Antibiotic Exposure with Residual Cancer Burden and Pathologic Complete Response in Patients with HER2-negative stage II or III breast cancer Treated with Neoadjuvant Pembrolizumab in the ISPY-2 Trial;2023-07-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3